Amedisys, Inc. (NASDAQ:AMED - Free Report) - Equities researchers at William Blair raised their FY2025 earnings per share estimates for shares of Amedisys in a research note issued on Thursday, April 24th. William Blair analyst M. Larew now forecasts that the health services provider will post earnings of $4.74 per share for the year, up from their previous forecast of $4.45. The consensus estimate for Amedisys' current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys' Q4 2025 earnings at $1.11 EPS.
Several other research firms have also recently weighed in on AMED. Stephens reissued an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Amedisys has a consensus rating of "Hold" and an average price target of $100.75.
Read Our Latest Analysis on Amedisys
Amedisys Stock Performance
NASDAQ:AMED opened at $94.50 on Monday. The firm has a market capitalization of $3.10 billion, a PE ratio of 37.50, a PEG ratio of 1.78 and a beta of 0.89. The firm's fifty day simple moving average is $92.21 and its 200 day simple moving average is $91.75. Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.
Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $594.78 million during the quarter, compared to analyst estimates of $597.43 million.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wealthquest Corp acquired a new position in Amedisys in the first quarter worth $1,310,000. FNY Investment Advisers LLC grew its stake in shares of Amedisys by 6,942.3% during the first quarter. FNY Investment Advisers LLC now owns 5,000 shares of the health services provider's stock valued at $463,000 after purchasing an additional 4,929 shares during the last quarter. Sagespring Wealth Partners LLC increased its holdings in shares of Amedisys by 12.3% in the first quarter. Sagespring Wealth Partners LLC now owns 3,237 shares of the health services provider's stock valued at $300,000 after purchasing an additional 354 shares in the last quarter. Exchange Traded Concepts LLC raised its position in Amedisys by 11.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 8,590 shares of the health services provider's stock worth $796,000 after purchasing an additional 887 shares during the last quarter. Finally, Fifth Third Bancorp lifted its holdings in Amedisys by 68.1% during the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock worth $32,000 after buying an additional 141 shares in the last quarter. 94.36% of the stock is owned by institutional investors.
About Amedisys
(
Get Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
